ResMed Inc. (RMD)
|Net Income (ttm)||474.51M|
|Ex-Dividend Date||Aug 18, 2021|
|Day's Range||265.20 - 268.36|
|52-Week Range||176.42 - 301.34|
|Price Target||261.33 (-2.5%)|
|Est. Earnings Date||Oct 28, 2021|
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software in... [Read more...]
In 2021, ResMed's revenue was $3.20 billion, an increase of 8.11% compared to the previous year's $2.96 billion. Earnings were $474.51 million, a decrease of -23.67%.Financial Statements
According to 10 analysts, the average rating for ResMed stock is "Hold." The 12-month stock price forecast is 261.33, which is a decrease of -2.48% from the latest price.
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strong customer demand and new product launches are likely to contribute to growth in the fiscal first quarter for ResMed (RMD).
Three healthcare stocks that have momentum on their side and are good buys right now.
SAN DIEGO, Oct. 07, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2022 on Thursday, Oct...
Investors are optimistic about ResMed (RMD) owing to new product launches in the SDB market and strong sales of mask products.
Consistency is the main attraction for these companies.
A late-breaking abstract from ResMed (RMD) supported landmark ALASKA study reported that treatment with PAP therapy improves the likelihood of longevity in sleep apnea patients
SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will participate in a virtual fireside chat at the Bank of ...
People with Sleep Apnea Live Longer on CPAP in Large, Late-Breaking ResMed-Supported ALASKA Study Presented at ERS
Continued PAP use linked to 39% higher chance of survival over a 3-year period Continued PAP use linked to 39% higher chance of survival over a 3-year period
David Pendarvis, Chief Administrative Officer at Resmed (NYSE:RMD), made a large insider sell on September 3, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and E...
James Hollingshead , President of Resmed (NYSE: RMD ), made a large insider sell on September 1, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Comm...
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will participate in a virtual fireside chat at the Morgan Stanley 19th A...
Change intended to drive rapid digital transformation, leverage full scale of cloud-connected technology platforms, and accelerate growth of ResMed's SaaS business Change intended to drive rapid digital...
ResMed's (RMD) new launch will make therapy setup easier for patients and help clinicians offer care more efficiently.
It doesn't take a brainiac to balance risk and reward.
Investors are optimistic about ResMed's (RMD) potential in digital health and its strong emphasis on product development.
New digital features designed to make therapy setup and nightly use easier for patients, and help clinicians provide care more efficiently New digital features designed to make therapy setup and nightly...
Final Trades: Alibaba, Resmed, Marathon Petroleum & more
The 'Halftime Report' traders give their top picks to watch for the second half.
Increased demand for sleep devices and masks, including recovery of core sleep patient flow, drove ResMed's (RMD) fiscal fourth-quarter growth.
ResMed (RMD) delivered earnings and revenue surprises of 8.00% and 12.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
It is imperative to build a portfolio of low-beta stocks to sail through choppy market conditions. VSTO, CAJ, AMEH, TYL and RMD are the frontrunners.